Our position, in plain language: PepiScreen is an independent peptide supplier audit and screening service, and a research and advocacy organisation focused on supplier accountability — in that order of priority. We do not sell, supply, prescribe, or dispense peptides. This page describes what we are, what we are not, and how we operate under the applicable Australian frameworks.
Written for registered health practitioners, industry professionals, regulators, and members of the public who want to understand where PepiScreen sits in the regulatory landscape. Last reviewed: 20 August 2026.
What PepiScreen is
PepiScreen is an independent peptide supplier audit and screening service, and a research and advocacy organisation focused on supplier accountability — in that order of priority. Specifically, we:
Maintain a register of 750+ peptide suppliers worldwide, compiled from public catalogues, third-party industry lists and our own research.
Audit peptide suppliers' Certificates of Analysis (COAs) against a published rubric of 27 evidence checks — 12 identity checks, 12 fraud pattern signals, and 3 community overlays — cross-referenced against that register. Detailed evidence data currently covers a growing subset in the low hundreds of certificates.
Verify testing laboratories against ISO 17025 accreditation and cross-check their published reports.
Publish aggregated market intelligence — a Peptide Guide, a Statement of Assurance, and (under Membership) the Peptide Suppliers Association (PSA) Member Directory.
Refer users to peptide-literate prescribing clinicians through our worldwide Doctors directory at pepiscreen.com/doctors/.
Operate a prescriber-mediated information framework through the Peptide Suppliers Association (PSA) Charter.
Register vs. audited evidence — an important distinction. The 750+ figure is our supplier register: the universe of sellers we have identified and can cross-reference an incoming certificate against. It is not a count of suppliers we have audited. Detailed audit evidence — scored certificates, tier bands, published verdicts — covers a much smaller subset. Both numbers are published deliberately: coverage of the market is meaningful, and so is honesty about the scope of the work we have done inside it.
What PepiScreen is not
PepiScreen does not:
Sell, supply, ship, or take payment for any peptide product.
Prescribe or dispense any therapeutic substance.
Provide medical advice or clinical services.
Perform laboratory analysis of physical vials — that is the role of a private analytical laboratory.
Substitute for consultation with a peptide-literate prescriber.
Accept advertising, sponsorship, or affiliate commissions from any peptide supplier.
The regulatory framework
AHPRA (Australian Health Practitioner Regulation Agency)
PepiScreen is not a registered health practitioner, health service, or provider of clinical services. We do not fall under the National Registration and Accreditation Scheme. Prescribing decisions belong to registered medical practitioners.
TGA (Therapeutic Goods Administration)
PepiScreen recognises the following applicable elements of the Australian therapeutic goods framework:
Most therapeutic peptides are Schedule 4 (prescription only) under the Poisons Standard.
The advertising of prescription medicines to the general public is prohibited under the Therapeutic Goods Act 1989 (s.42DL), including indirect promotion.
The Therapeutic Goods Advertising Code governs both direct and indirect promotional content.
Peptides that are Schedule 4 may only be legally supplied on prescription from a registered health practitioner.
Peptides not on the Australian Register of Therapeutic Goods (ARTG) fall under the same restrictions when supplied for therapeutic use.
PepiScreen's role is to provide independent evidence assessment, not to advertise or facilitate supply of prescription medicines. We publish evidence-based assessments intended to inform prescribers and their patients, and to raise industry standards among suppliers.
How we operate — our principles
Evidence-first. We publish assessments of supplier documentation against a published rubric. No promotional content, no supplier-paid placement.
Prescriber-mediated. Every relevant page directs users to consult a peptide-literate prescriber. Our Guide to Using Peptides opens with "See a peptide-literate doctor first" as step one.
Directory as a professional trade register. The Peptide Suppliers Association (PSA) Member Directory is a professional trade register for prescribers, industry professionals, and buyers working with a clinician — not a public consumer shopping catalogue.
Independent revenue. We accept no advertising, no sponsorship, and no affiliate commissions from any peptide supplier. Our revenue is from audit fees paid by the person requesting the audit.
Where a specific vial's content matters. We direct to private analytical laboratory testing. Our audit is documentary evidence assessment; it is not a substitute for laboratory analysis of a specific vial.
Open to scrutiny. Our Statement of Assurance at pepiscreen.com/assurance/ publishes our full evaluation methodology, the role of AI, human oversight, and the explicit limits of what our scores can and cannot tell you.
Harm-reduction context
Peptide consumption is a widespread reality of the current market. In the absence of independent evidence, buyers rely on vendor marketing and forum posts. The realistic alternative to independent supplier screening is not zero peptide use — it is the same use, informed by less reliable sources.
PepiScreen exists to provide the missing evidence layer: to help prescribers assess supplier documentation, to help patients ask their prescriber informed questions, and to raise industry standards by making documentation quality visible.
Any clinician, regulator, industry participant, or member of the public who wishes to review our methodology in more depth, request evidence of the practices described above, or raise a concern:
We welcome dialogue with registered health practitioners and Australian regulators. If a specific piece of site copy raises a concern, please tell us — copy changes are made routinely in response to specific feedback.